VIP: a real neuropeptide, attached to a protocol that is not consensus medicine
Two separate things share this page. VIP is a real, well-studied endogenous neuropeptide. The reason most people encounter it is a specific practitioner protocol for a diagnosis that mainstream medicine does not recognise, and those deserve to be separated.
Regulatory status. Research compound — no FDA approval. Compounded from specialized pharmacies. Cornerstone of Shoemaker CIRS protocol. That is the app’s own field, reproduced here rather than summarised. It means no regulator has reviewed a manufacturer’s evidence for identity, purity, potency or safety in people for this compound, so nothing below is a marketing claim about a product you can buy.
Purity, identity and concentration are therefore unverified by anyone but whoever made the vial. The storage rule in the fact box below is general practice for this formulation rather than a specification for a particular product: General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
This page names no vendor, no clinic and no testing service, and there is no discount code anywhere on this site — the moment a page like this recommends where to buy, it stops being information.
- Also known as
- Vasoactive Intestinal Peptide
- Class
- Metabolic and cardiovascular
- Regulatory status
- Research compound — no FDA approval. Compounded from specialized pharmacies. Cornerstone of Shoemaker CIRS protocol.
- Before mixing
- Sealed powder tolerates room temperature in transit, but keep it refrigerated at 2–8 °C (36–46 °F) for anything beyond a few weeks, or frozen for months. Keep it dark — the carton it shipped in is doing a job.
- After mixing
- Once reconstituted with bacteriostatic water: refrigerate at 2–8 °C and use within about 28 days. The benzyl alcohol in bacteriostatic water is what buys that window — plain sterile water has no preservative, so a vial mixed with it should be treated as one sitting only. Kits are usually ten vials: only the one you mixed is on that 28-day clock — the sealed ones keep their own, much longer shelf life, so store them as powder, not as solution.
- What ruins it
- Do not freeze a reconstituted vial. Repeated freeze–thaw is one of the more reliable ways to degrade a peptide.
- Handling caveat
- General handling practice for this formulation. Your supplier’s own insert or COA overrides anything here.
The physiology is not in doubt
Established clinical use Vasoactive intestinal peptide is a 28-amino-acid neuropeptide found throughout the nervous system, the gut and the immune system. It is a potent vasodilator, a bronchodilator, a regulator of intestinal secretion, and one of the more powerful endogenous anti-inflammatory signals known — it shifts immune responses away from inflammatory patterns and promotes regulatory T-cell activity. It is also the principal neurotransmitter of the suprachiasmatic nucleus, which is the body clock.
That is textbook physiology rather than a claim, and it is why VIP has been of pharmaceutical interest for conditions including pulmonary arterial hypertension and sarcoidosis. Its problem as a drug is delivery: it is cleared in minutes, which is why the routes described are intranasal or inhaled rather than anything systemic and lasting. The app records no half-life for the preparations in use, which is why the fact box carries no pharmacokinetic rows.
The protocol, described accurately
Off-label or community practice In this space VIP is known almost entirely through one framework: a practitioner-developed protocol for chronic inflammatory response syndrome, attributed to water-damaged buildings and biotoxin exposure, in which VIP is the final step after other interventions. The app’s own dosing rows name it.
Being precise about its status matters. CIRS as defined by that protocol is not a diagnosis recognised by mainstream medical bodies, its proposed biomarker panel — TGF-beta1, C4a, MMP-9, MSH — is not validated for that purpose, and the protocol as a whole has not been through controlled trials. That is not an accusation that the people using it are unwell in no way; chronic fatigue, cognitive difficulty and multi-system symptoms are real, and patients arriving at this protocol have usually been failed elsewhere. It is a statement about what has been demonstrated.
The honest reading is that a genuinely anti-inflammatory endogenous peptide has been attached to an unvalidated diagnostic framework, and the strength of the first does not transfer to the second. Anyone considering it should know which part rests on textbook physiology and which part does not.
Practical considerations
There is no approved product. What is used is compounded, typically as an intranasal preparation, and identity, concentration and sterility rest with the compounder. This site names no pharmacy, clinic or testing service. It is also expensive relative to almost everything else in this reference.
Established clinical use The predictable effects follow from the pharmacology: flushing and hypotension, because it is a potent vasodilator. That is a real consideration for anyone already on blood-pressure medication or prone to orthostatic symptoms, and it is why the app puts blood pressure on the monitoring list.
The markers the protocol calls for are specialty tests with their own interpretive problems, and a result on an unvalidated panel is not a finding. Anyone with persistent multi-system symptoms deserves a diagnostic workup that excludes the things that are treatable and well characterised first, and that is the conversation to have with a clinician before this one.
The dosing rows the app records
Off-label or community practice Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.
| Label | Amount | Route and frequency | Duration recorded |
|---|---|---|---|
| CIRS / MCAS (Intranasal) | 50mcg 4x/day | Intranasal insufflation | Ongoing — as part of Shoemaker Protocol |
| Anti-inflammatory (Intranasal) | 25-50mcg | Intranasal 2-4x daily | 4-12 weeks |
| Anti-inflammatory (SubQ) | 25-50mcg | Subcutaneous injection 1-2x daily | 4-12 weeks — research use |
What the app monitors alongside it
The panel below is the app’s own monitoring note for VIP, verbatim. None of the analytes it names has a page here yet.
- Monitoring panel
- Inflammatory markers (TGF-beta1, C4a, MMP-9 for CIRS), MSH (melanocyte stimulating hormone), VIP levels if testable, blood pressure.
Drawbacks and risks the app records
From the app’s own entry, and the physician-guidance item is the one that matters most here — less because of the peptide than because of what it is being used to treat.
- Very short half-life — intranasal or inhaled dosing required
- Flushing and hypotension possible at higher doses
- Very expensive
- Limited availability — specialized compounding pharmacies
- Not FDA approved
- Should be used under physician guidance for CIRS
Interaction rules that name VIP
From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.
VIP + BPC-157 — Comprehensive Gut and Immune Stack
VIP and BPC-157 address gut inflammation via completely different mechanisms — VIP via mast cell stabilization and vasodilation, BPC-157 via tissue repair and GH receptor upregulation. Together they form a comprehensive gut and immune repair protocol.
What to watch: Inflammatory markers (TGF-beta1, C4a for CIRS), gut symptom tracking, blood pressure (VIP can cause hypotension).
Questions people actually ask
Is CIRS a recognised diagnosis?
Not by mainstream medical bodies, and the biomarker panel associated with it is not validated for that use. The symptoms people bring to it are real; the framework interpreting them has not been through the process that would establish it.
Is VIP itself well studied?
As physiology, yes — it is textbook material with a substantial literature. As a therapy delivered intranasally for the indications it is used for here, no.
Why intranasal?
Because it is cleared in minutes, so a systemic route achieves little. Intranasal delivery is an attempt to reach the central nervous system directly, which is a reasonable strategy and not a demonstrated one.
What are the immediate effects to expect?
Flushing and a drop in blood pressure, both predictable from a potent vasodilator. That matters for anyone on antihypertensives or prone to orthostatic symptoms, and it is why blood pressure is on the monitoring list.
Where the load-bearing numbers come from
Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.
- VIP physiology
- Standard references on neuropeptide and immune physiology; the anti-inflammatory and vasodilatory roles are well established
- Status of the CIRS framework
- Not recognised as a diagnosis by mainstream medical bodies; the associated biomarker panel is not validated for the purpose
- Absence of controlled trials for the protocol
- The protocol as a whole has not been evaluated in randomised trials
- Absence of pharmacokinetic data
- app.html holds no half-life or time-to-peak entry for the preparations in use
A protocol with many steps and specialty labs is one where the sequence and the dates matter. TherapyLog keeps them straight.
Save this dose to your log